Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852276 | 0.88 | DRD2 (0.52) | DRD2CCR3JAK2JAK1HRH3 | |
| SCHEMBL5102691 | 0.85 | HRH3 (0.50) | CCR3HRH3CARM1PRMT6HRH1 | |
| SCHEMBL5098799 | 0.84 | CCR3 (0.48) | DRD2CCR3HRH3CARM1PRMT6 | |
| SCHEMBL5102255 | 0.80 | CARM1 (0.65) | HRH3CARM1PRMT6 | |
| SCHEMBL5656318 | 0.80 | HRH1 (0.58) | DRD2CCR3HRH1 | |
| SCHEMBL1446180 | 0.78 | EGFR (0.61) | — | |
| SCHEMBL2774468 | 0.78 | GPR119 (0.71) | GPR119CCR3HRH3HRH1 | |
| SCHEMBL26306413 | 0.78 | DRD2 (0.58) | DRD2CARM1PRMT6 | |
| SCHEMBL7186721 | 0.77 | CARM1 (0.45) | DRD2CCR3HRH3CARM1PRMT6 | |
| SCHEMBL23142741 | 0.76 | DDB1 (0.49) | DRD2CCR3JAK2JAK1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304077-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-12-04 | — | — | US | disclosed |
| US-20040102432-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102432-A1 | Chemical compounds | CCL11, HRH1, HRH4 | DRD2 1111/4885GPR119 354/4885CCR3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.